• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Total number of clinical trials
  • A multicenter, single arm, cohort study to evaluate the Efficacy and Safety of saxagliptin 5mg, once daily for 24 weeks, in patients with type 2 diabetes mellitus who are treatment naïve or who have inadequate glycaemic control on metformin alone

Disease
diabetes mellitus, diabetes type 2
Drug Name
Onglyza, saxagliptin
Sponsor
AstraZeneca
Drug Status
Approved Medicine
Phase
IV
Start Date
Jan 18, 1971
Study Name
SUNSHINE
ClinicalTrials.gov ID
NCT01608724
Recruiting Status
Open
Protocol Status
Not Available
Report Status
Not Available

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013